Insulet Corporation $PODD Shares Sold by Swedbank AB

Key Points

• Swedbank AB has reduced its stake in Insulet Corporation (NASDAQ:PODD) by 9.9% during Q1, owning approximately 0.07% of the company valued at $12.7 million after selling 5,300 shares.
• Insulet reported a 32.9% year-over-year increase in revenue for the last quarter, achieving $649.1 million and earnings per share of $1.17, exceeding analysts' expectations.
• A number of analysts have increased their price objectives for Insulet's stock, with Oppenheimer raising their target to $365.00 and the stock currently holding a "Moderate Buy" rating among sixteen equities research analysts.

Swedbank AB cut its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 9.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 48,388 shares of the medical instruments supplier's stock after selling 5,300 shares during the quarter. Swedbank AB owned about 0.07% of Insulet worth $12,707,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. Captrust Financial Advisors grew its stake in shares of Insulet by 24.1% during the 4th quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier's stock worth $570,000 after purchasing an additional 425 shares during the period. Janus Henderson Group PLC grew its stake in Insulet by 7.0% in the 4th quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier's stock valued at $2,049,000 after acquiring an additional 511 shares during the last quarter. NorthRock Partners LLC acquired a new stake in Insulet in the 4th quarter valued at about $267,000. Nissay Asset Management Corp Japan ADV grew its stake in Insulet by 0.9% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 8,414 shares of the medical instruments supplier's stock valued at $2,231,000 after acquiring an additional 78 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in Insulet by 12.3% in the 4th quarter. ProShare Advisors LLC now owns 10,614 shares of the medical instruments supplier's stock valued at $2,771,000 after acquiring an additional 1,159 shares during the last quarter.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Trading Up 1.1%

Shares of PODD stock opened at $341.78 on Monday. The firm has a market cap of $24.06 billion, a P/E ratio of 103.88, a PEG ratio of 2.84 and a beta of 1.36. Insulet Corporation has a 1-year low of $225.37 and a 1-year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm's 50-day simple moving average is $311.59 and its 200-day simple moving average is $292.31.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Oppenheimer increased their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. Truist Financial assumed coverage on shares of Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Canaccord Genuity Group increased their price objective on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $335.12.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.